$PHAR News

Pharming Q3 2026 Earnings Call Transcript

Pharming Group N.V. 2026 Q3 - Results - Earnings Call Presentation

Pharming Affirms FY2026 Sales Guidance of $380.000M-$390.000M vs $383.333M Est

Pharming Q3 EPS $0.30 Beats $0.02 Estimate, Sales $117.600M Miss $117.733M Estimate

Pharming Group announces third quarter 2026 revenues above market expectations

Pharming Narrows FY2026 Sales Guidance from $375.000M-$395.000M to $380.000M-$390.000M vs $389.333M Est

Pharming Reports Preliminary Q3 Revenues $117.6M, Up 21% YoY; Operating Expenses $74.6M Vs $74.5M YoY; Napazimone FALCON Trial Enrollment Now Expected Complete In First Half 2027, 2026 Revenue Guidance Tightened To $380M-$390M From $375M-$395M

Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026

Pharming Says Leniolisib Reduced Spleen Volume In 10 Of 11 Evaluable Participants And Lymph Node Size In All 4 In Phase II Genetic PID Trial, With No New Safety Signals

Pharming Group: Viable Contrarian Buy If Ruconest Stabilizes

Pharming announces CEO transition

Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS

HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target

Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026

Pharming Group (PHAR) Expands Joenja’s Pediatric Label. Can Growth Offset RUCONEST Weakness?

Pharming Group N.V. (PHAR) Presents at H.C. Wainwright 28th Annual Global Investment Conference - Slideshow

HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target

FDA approves Pharming's Joenja® as first treatment for children with APDS in the U.S.

Pharming Wins FDA Approval For Joenja In Children Ages 4 To 11 Who Weigh At Least 27kg, With New 40mg/50mg Twice-Daily Doses Expected In October

Pharming Group to participate in September investor conferences